A Mechanistic Model for Predicting Cell Surface Presentation of Competing Peptides by MHC Class I Molecules
暂无分享,去创建一个
Andrew Phillips | Peter V. Coveney | Neil Dalchau | Tim Elliott | P. Coveney | T. Elliott | N. Dalchau | A. Phillips | Denise S. M. Boulanger | Ruth C. Eccleston | R. C. Eccleston | D. Boulanger | Andrew Phillips | Neil Dalchau
[1] G. Merlino,et al. The Two Faces of Interferon-γ in Cancer , 2011, Clinical Cancer Research.
[2] L. Kaer,et al. Impaired assembly yet normal trafficking of MHC class I molecules in Tapasin mutant mice. , 2000, Immunity.
[3] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[4] Georg Seelig,et al. A spatially localized architecture for fast and modular DNA computing. , 2017, Nature nanotechnology.
[5] Luca Cardelli,et al. A Peptide Filtering Relation Quantifies MHC Class I Peptide Optimization , 2011, PLoS Comput. Biol..
[6] Hoon Kim,et al. Monte Carlo Statistical Methods , 2000, Technometrics.
[7] M. Hollingsworth,et al. Tapasin Decreases Immune Responsiveness to a Model Tumor Antigen , 2004, Journal of Clinical Immunology.
[8] T. Elliott,et al. Tapasin shapes immunodominance hierarchies according to the kinetic stability of peptide – MHC class I complexes , 2008, European journal of immunology.
[9] L. Jensen,et al. Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation* , 2015, Molecular & Cellular Proteomics.
[10] Lloyd J. Old,et al. The roles of IFNγ in protection against tumor development and cancer immunoediting , 2002 .
[11] T. Elliott,et al. CD8+ T-cell cross-competition is governed by peptide–MHC class I stability , 2011, European journal of immunology.
[12] M. Garcia-Peydró,et al. Quantitative and Qualitative Influences of Tapasin on the Class I Peptide Repertoire1 , 2001, The Journal of Immunology.
[13] Ilan Beer,et al. The Turnover Kinetics of Major Histocompatibility Complex Peptides of Human Cancer Cells* , 2006, Molecular & Cellular Proteomics.
[14] J. Yewdell,et al. The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation. , 2008, Immunity.
[15] E. Caron,et al. The MHC class I peptide repertoire is molded by the transcriptome , 2008, The Journal of experimental medicine.
[16] Markus Müller,et al. High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome* , 2017, Molecular & Cellular Proteomics.
[17] Manoj Bhasin,et al. Analysis and prediction of affinity of TAP binding peptides using cascade SVM , 2004, Protein science : a publication of the Protein Society.
[18] T. Rau,et al. Loss of tapasin correlates with diminished CD8+ T-cell immunity and prognosis in colorectal cancer , 2015, Journal of Translational Medicine.
[19] A. Goldberg,et al. Re-examining class-I presentation and the DRiP hypothesis. , 2014, Trends in immunology.
[20] T. Elliott,et al. Selector function of MHC I molecules is determined by protein plasticity , 2015, Scientific Reports.
[21] Michelle S. Scott,et al. A Quantitative Spatial Proteomics Analysis of Proteome Turnover in Human Cells* , 2011, Molecular & Cellular Proteomics.
[22] Charlotte M. Deane,et al. Rapid, Precise, and Reproducible Prediction of Peptide-MHC Binding Affinities from Molecular Dynamics That Correlate Well with Experiment. , 2015, Journal of chemical theory and computation.
[23] James McCluskey,et al. Optimization of the MHC class I peptide cargo is dependent on tapasin. , 2002, Immunity.
[24] Peter V. Coveney,et al. The Role of Multiscale Protein Dynamics in Antigen Presentation and T Lymphocyte Recognition , 2017, Front. Immunol..
[25] T. Elliott,et al. Absence of Tapasin Alters Immunodominance against a Lymphocytic Choriomeningitis Virus Polytope , 2009, The Journal of Immunology.
[26] Akira Hattori,et al. An IFN-γ–induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I–presented peptides , 2002, Nature Immunology.
[27] Ruedi Aebersold,et al. Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry. , 2015, Molecular & cellular proteomics : MCP.
[28] S. Stevanović,et al. TAPBPR bridges UDP-glucose:glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control in the antigen presentation pathway , 2017, eLife.
[29] Anthony W. Purcell,et al. Kinetics of Antigen Expression and Epitope Presentation during Virus Infection , 2013, PLoS pathogens.
[30] Ö. Türeci,et al. Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines , 2016, Clinical Cancer Research.
[31] S. Brunak,et al. Prediction of proteasome cleavage motifs by neural networks. , 2002, Protein engineering.
[32] J. Yewdell,et al. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. , 2006, Immunity.
[33] Bjoern Peters,et al. Naive Precursor Frequencies and MHC Binding Rather Than the Degree of Epitope Diversity Shape CD8+ T Cell Immunodominance1 , 2008, The Journal of Immunology.
[34] R. Schreiber,et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .
[35] Peter V Coveney,et al. Host genotype and time dependent antigen presentation of viral peptides: predictions from theory , 2017, Scientific Reports.
[36] Anthony W. Purcell,et al. Constitutive and Inflammatory Immunopeptidome of Pancreatic β-Cells , 2012, Diabetes.
[37] Philip E. Bourne,et al. Immune epitope database analysis resource , 2012, Nucleic Acids Res..
[38] Ilan Beer,et al. The Effect of Proteasome Inhibition on the Generation of the Human Leukocyte Antigen (HLA) Peptidome* , 2013, Molecular & Cellular Proteomics.
[39] J. Drijfhout,et al. Cross-presentation by intercellular peptide transfer through gap junctions , 2005, Nature.
[40] K. Parker,et al. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.
[41] Arie Admon,et al. The nature and extent of contributions by defective ribosome products to the HLA peptidome , 2014, Proceedings of the National Academy of Sciences.
[42] W. Gillanders,et al. Personalized cancer vaccines: Targeting the cancer mutanome. , 2017, Vaccine.
[43] George Coukos,et al. Mass spectrometry-based antigen discovery for cancer immunotherapy. , 2016, Current opinion in immunology.
[44] T. Elliott,et al. Differential Suppression of Tumor-Specific CD8+ T Cells by Regulatory T Cells , 2010, The Journal of Immunology.
[45] J. Yewdell,et al. Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors , 2014, Journal of leukocyte biology.
[46] J. Yewdell,et al. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. , 1997, Immunity.
[47] T. Elliott,et al. Tapasin enhances MHC class I peptide presentation according to peptide half-life. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[48] T. Elliott,et al. The cell biology of major histocompatibility complex class I assembly: towards a molecular understanding. , 2010, Tissue antigens.
[49] A. Diehl,et al. Impaired immune responses and altered peptide repertoire in tapasin-deficient mice , 2000, Nature Immunology.
[50] Özlem Türeci,et al. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma , 2013, BMC Genomics.
[51] J. Luke,et al. Mechanistic and pharmacologic insights on immune checkpoint inhibitors , 2017, Pharmacological research.
[52] J. Yewdell,et al. Compartmentalized MHC class I antigen processing enhances immunosurveillance by circumventing the law of mass action , 2010, Proceedings of the National Academy of Sciences.
[53] R. Schreiber,et al. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. , 2005, Cancer research.
[54] Morten Nielsen,et al. Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..
[55] J. Leunissen,et al. The Human Leukocyte Antigen–presented Ligandome of B Lymphocytes* , 2013, Molecular & Cellular Proteomics.
[56] A. Chakraborty,et al. T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation , 2008, Nature Immunology.
[57] Ilka Hoof,et al. Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A and B in the Immunopeptidome , 2015, PloS one.
[58] J. Yewdell,et al. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? , 1996, Journal of immunology.